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Abstract
Background: Antitumor cyclopalladated complexes with low toxicity to laboratory animals have shown leishmanicidal
effect. These findings stimulated us to test the leishmanicidal property of one palladacycle compound called DPPE 1.2 on
Leishmania (Leishmania) amazonensis, an agent of simple and diffuse forms of cutaneous leishmaniasis in the Amazon
region, Brazil.
Methodology/Principal Findings: Promastigotes of L. (L.) amazonensis and infected bone marrow-derived macrophages
were treated with different concentrations of DPPE 1.2. In in vivo assays foot lesions of L. (L.) amazonensis-infected BALB/c
mice were injected subcutaneously with DPPE 1.2 and control animals received either Glucantime or PBS. The effect of DPPE
1.2 on cathepsin B activity of L. (L.) amazonensis amastigotes was assayed spectrofluorometrically by use of fluorogenic
substrates. The main findings were: 1) axenic L. (L.) amazonensis promastigotes were destroyed by nanomolar
concentrations of DPPE 1.2 (IC50=2.13 nM); 2) intracellular parasites were killed by DPPE 1.2 (IC50=128.35 nM), and the
drug displayed 10-fold less toxicity to macrophages (CC50=1,267 nM); 3) one month after intralesional injection of DPPE 1.2
infected BALB/c mice showed a significant decrease of foot lesion size and a reduction of 97% of parasite burdens when
compared to controls that received PBS; 4) DPPE 1.2 inhibited the cysteine protease activity of L. (L.) amazonensis
amastigotes and more significantly the cathepsin B activity.
Conclusions/Significance: The present results demonstrated that DPPE 1.2 can destroy L. (L.) amazonensis in vitro and in
vivo at concentrations that are non toxic to the host. We believe these findings support the potential use of DPPE 1.2 as an
alternative choice for the chemotherapy of leishmaniasis.
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Introduction
Protozoan parasites of the Leishmania genus induce cutaneous,
mucocutaneous and visceral diseases in man and animals.
According to the World Health Organization, about 1.5 million
of new human cases of cutaneous leishmaniasis and 500,000 of
visceral leishmaniasis are registered annually [1]. Leishmania
(Leishmania) amazonensis, one of the causative agents of human
cutaneous leishmaniasis in the Amazon region, Brazil, is associated
with both the simple and diffuse forms of the disease [2]. The first-
line drugs used for treatment of leishmaniasis are pentavalent
antimonial compounds, while amphotericin B and pentamidine
are used as the second-line chemotherapy. However, the use of
these compounds is limited by toxicity to the host and the
development of resistance by the parasites [3,4]. Thus, the
development of new leishmanicidal drugs is an important goal
and several compounds including synthetic, natural products
extracted from plants and marine sources have shown different
degrees of efficacy in the treatment of experimental leishmaniasis
[5–7]. The in vitro and in vivo demonstration that the viability of the
Leishmania parasites is reduced by inhibitors of cysteine proteases
[8–10] encouraged the use of virtual screening to identify
additional inhibitors [11,12]. The demonstration that antitumor
drugs may also display antileishmanial activity has also stimulated
the screening of these compounds in vitro and in clinical trials [13].
Cyclopalladated complexes have shown in vitro and in vivo
antitumor activity and low toxicity in animals [14–16] and more
recently one of them exhibited lethal effects on human leukaemia
cells while was ineffective against normal human lymphocytes
[17]. The leishmanicidal and tripanocidal activity of cyclopalla-
dated complexes has also been demonstrated [18–20]. Further-
more, there is evidence that palladacycle complexes may destroy
tumoral cells by inhibition of cathepsin B activity and their
inhibitory effect on Leishmania cysteine proteases in vitro was also
demonstrated [18,21]. The present study describes the effect of
one palladacycle compound called DPPE 1.2 on promastigotes,
intracellular amastigotes and cutaneous lesions in mice infected
with L. (L.) amazonensis.
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Animals
Eight-week-old female Golden hamsters were obtained from
breeding stocks maintained at the Universidade de Campinas (Sa ˜o
Paulo, Brazil) and female BALB/c mice 6 to 8 weeks old were
acquired from Universidade Federal de Sa ˜o Paulo (Sa ˜o Paulo,
Brazil). This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Brazilian National Council of Animal
Experimentation (http://www.cobea.org.br). The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Institutional Animal Care and Use Committee at the
Federal University of Sa ˜o Paulo (Id # CEP 1844/08).
Parasites
The L. (L.) amazonensis strain used (MHOM/BR/1973/M2269)
was kindly provided by Dr. Jeffrey J. Shaw, Instituto Evandro
Chagas, Bele ´m, Para ´, Brazil and maintained as amastigotes by
inoculation into footpads of Golden hamsters every 4 to 6 weeks.
Amastigote suspensions were prepared by homogenization of
excised lesions, disruption by four passages through 22-gauge
needles, and centrifugation at 2506g for 10 min; the resulting
supernatant was centrifuged at 1,4006g for 10 min, and the pellet
was resuspended in RPMI 1640. The suspension was kept under
agitation for 4 h at room temperature and centrifuged at 2506g
for 10 min. The final pellet contained purified amastigotes which
were essentially free of contamination by other cells [22].
L. (L.) amazonensis promastigotes were grown at 26uC in 199
medium (Gibco) supplemented with 4.2 mM sodium bicarbonate,
4.2 mM HEPES, 1 mM adenine, 5 mg/ml hemin (bovine type I)
(Sigma, St Louis, MO, USA) and 10% fetal calf serum (FCS)
(Cultilab, SP, Brazil).
Biphosphinic palladacycle complex [Pd(C2,
N-S(-)DMPA)(DPPE)]Cl (DPPE 1.2)
The palladacycle compound DPPE 1.2 (Figure 1) was obtained
from N,N-dimethyl-1-phenethylamine (DMPA), complexed to 1,2-
ethane-bis (diphenylphosphine) (DPPE) ligand and synthesized as
previously described [16]. Stock solutions at 1.45 mM were
prepared in dimethylsulfoxide (DMSO); for in vitro use, the drug
was diluted to the appropriate concentration in cell culture
medium, and for in vivo injections the stock was diluted in PBS.
Author Summary
Leishmaniasis is an important public health problem with
an estimated annual incidence of 1.5 million of new
human cases of cutaneous leishmaniasis and 500,000 of
visceral leishmaniasis. Treatment of the diseases is limited
by toxicity and parasite resistance to the drugs currently in
use, validating the need to develop new leishmanicidal
compounds. We evaluated the killing by the palladacycle
complex DPPE 1.2 of Leishmania (Leishmania) amazonensis,
an agent of human cutaneous leishmaniasis in the Amazon
region, Brazil. DPPE 1.2 destroyed promastigotes of L. (L.)
amazonensis in vitro at nanomolar concentrations, whereas
intracellular amastigotes were killed at drug concentra-
tions 10-fold less toxic than those displayed to macro-
phages. L. (L.) amazonensis-infected BALB/c mice treated
by intralesional injection of DPPE 1.2 exhibited a significant
decrease of foot lesion sizes and a 97% reduction of
parasite burdens when compared to untreated controls.
Additional experiments indicated the inhibition of the
cathepsin B activity of L. (L.) amazonensis amastigotes by
DPPE 1.2. Further studies are needed to explore the
potential of DPPE 1.2 as an additional option for the
chemotherapy of leishmaniasis.
Figure 1. Structure of the DPPE 1.2 compound [Pd(C2, N-S(-)DMPA)(DPPE)]Cl.
doi:10.1371/journal.pntd.0001626.g001
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Thepromastigoteculturesat1610
6 parasites/mlwerekeptin199
culture medium as described above containing between 1.25 nM
and 150 nM of DPPE 1.2. Parasites were counted daily in a
Neubauer chamber for three days. The leishmanicidal effect of
DPPE 1.2 on intracellular amastigotes was evaluated in mouse bone
marrow derived macrophages infected with L. (L.) amazonensis.B o n e
marrow-derived macrophages were generated from bone marrow
stem cells isolated from BALB/c mice [23]. Cells were counted,
added (8610
5) and cultured on glass coverslips inserted in 24-well
tissue culture plates containing RPMI 1640 medium buffered with
15 mM of HEPES, 20 mM of sodium bicarbonate and supple-
mented with 1 mM L-glutamine, 20% of fetal calf serum (FCS) and
30% L929 cell conditioned medium (LCCM). Cultures were kept at
37uC in an atmosphere of air/CO2 (95/5%). After 5 days, the
medium was changed for RPMI containing 10% of FCS and
macrophages were infected at a multiplicity of 2 amastigotes per
macrophage.After 24 h, infected cultureswere treated with different
drug concentrations (150 to 500 nM) for 3 days. The coverslips were
fixed with methanol, stained with hematoxylin-eosin (HE) and
intracellular amastigotes were counted. Results are expressed by the
infection index, obtained by multiplying the percentage of infected
macrophages by the average number of amastigotes per macro-
phage. At least 200 macrophages were scored in each 3 coverslips.
Amphotericin B (Sigma-Aldrich, St Louis, MO, USA) and
Glucantime (Sanofi-Aventis, Brazil, 300 mg/ml, 81 mg/ml Sb
V)
were used as standard drugs for treatment of L. (L.) amazonensis
promastigotes and intracellular amastigotes, respectively.
Cytotoxicity assays
DPPE 1.2 cytotoxicity to macrophages was tested by a MTT
micromethod described previously [24] after incubation of bone
marrow derivedmacrophageswith150to2,000 nMofDPPE1.2for
3 days. Macrophages were also incubated with the highest
concentration of DMSO used for DPPE 1.2 solubilization (0.04%).
The formation of formazan was measured by adding 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Mo-
lecular Probes, Eugene, OR, USA) 0.5 mg/ml and incubation of the
cultures at 37uC in the dark. After 4 h the medium was removed,
200 ml of DMSO was added per well and the absorbance was
measured using an ELISAreader at 540 nm (Labsystems Multiskan).
Antileishmanial in vivo assays
For evaluation of in vivo leishmanicidal activity of DPPE 1.2
female BALB/c mice 6 to 8 weeks-old were infected subcutaneously
at the right hind-foot with 1610
5 L. (L.) amazonensis amastigotes.
Fifteen days after infection, the animals were randomly separated in
3 groups of 12 mice each. Treated animals received in the foot
lesions every other day doses of 60 mg/kg/day (16.8 mg [Sb
v]/kg/
day)ofGlucantime for1 month (totalof900 mg/kg–252 mg[Sb
v]/
kg/day) or doses of 320 mg/kg/day of DPPE 1.2 (total of 4.8 mg/
kg). Stock solutions of DPPE 1.2 were prepared daily in PBS after
solubilization in DMSO (final concentration of 0.1%). Control
group received the same number of injections of PBS. Infection was
monitored once a week by measuring the diameter of foot lesions
with a dial caliper (Mitutoyo Corp., Japan). Parasite burden from
infected feet was determined by a limiting dilution method, as
previously described [25].
Toxicity for mice assays
Serum concentrations of urea, creatinine, bilirubin and
transaminases were determined in BALB/c mice at the end of
treatment, using sets of commercial reagents (Doles Reagentes e
Equipamentos para Laborato ´rios, Ltda, Brazil).
Proteolytic activity
Proteolytic activity of L. (L.) amazonensis promastigotes and
amastigotes was determined by zymography employing electro-
phoretic separation of parasite lysates under unheated and
nonreduced conditions resolved on 10% acrylamide gels contain-
ing 0.1% copolymerized gelatin (Gibco-BRL) by low-voltage
(50 V) electrophoresis [26]. Proteolytic activity in the gels was
detected after 1 h of incubation, under agitation, in 0.1 M sodium
acetate buffer, pH 5.0, containing 2.5% Triton X-100, followed
by 2 h of incubation in the acetate buffer in the absence of Triton
X-100 and Coomassie blue staining. Some gel strips after
electrophoresis were incubated in buffer solutions in the presence
of either protease inhibitor E-64 (trans-epox-isuccinil-L-leucina-
mide-(4-guanide-butane) or orthophenanthroline or DPPE 1.2.
Molecular weight markers (Pharmacia LKB) were visible on the
background of stained gelatin when used in a 5-fold excess.
Inhibition of L. (L.) amazonensis cathepsins by DPPE 1.2
Cathepsin activities were monitored with the fluorogenic
substrates Z-Phe-Arg-AMC (for all cathepsins), Z-Arg-Arg-AMC
(for cathepsin B), and Z-Leu-Arg-AMC (for cathepsins K, V, and
S) (commercially obtained from Sigma, St. Louis, MO, USA) using
1 mlo fL. (L.) amazonensis amastigote cell lysate (1610
9 amastigotes
disrupted in 200 ml PBS), 2 mM DTT (dithiothreitol), 1 ml of
four-component buffer comprised of 25 mM acetic acid, 25 mM
Mes (4-Morpholineethanesulfonic acid), 75 mM Tris, and 25 mM
glycine, pH 5.0, 10 mM of each fluorogenic substrate and 50 mM
of DPPE 1.2. The effect of DPPE 1.2 on the parasite enzyme
activity was tested by incubation of the L. (L.) amazonensis lysate
with DPPE 1.2 for 2 minutes in the buffer solution a 37uC; the
fluorogenic substrate was then added and the fluorescence of the
released fluorophore, 7-amino-4-methylcoumarine (AMC), was
measured over time. The remaining enzyme activities were
determined and expressed as a percentage of the activity of the
control experiment. Parasite lysate was also incubated with 10 mM
of the fluorogenic substrate Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-
OH (Sigma, St. Louis, MO, USA), specific for cathepsin B [27], in
the presence of either increasing concentrations of DPPE 1.2 or
CA074, a specific inhibitor of cathepsin B. The cathepsin activity
was monitored spectrofluorometrically using the fluorogenic
substrates on a Hitachi F-2000 spectrofluorometer equipped with
a thermostated cell holder. The fluorescence excitation (lEx) and
emission (lEm) wavelengths, for the fluorescence of AMC, were
set at 380 nm and 460 nm, respectively, while the parameters for
the fluorescence of Abz-peptide fragments resulting from the
Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH hydrolysis were set at
lEx=320 and lEm=420 nm.
Statistical analysis
To determine the statistical differences between groups
ANOVA and Student’s t test were used and P values,0.05 or
lower were considered statistically significant. IC50 and CC50
values were determined by GraphPad Prism, version 5.0.
Results
Inhibitory activity of DPPE 1.2 on growth of L. (L.)
amazonensis promastigotes
Axenic cultures of L. (L.) amazonensis promastigotes were grown
in the presence of 1.25 to 150 nM of DPPE 1.2. Significant
inhibition of parasite growth was detected after 2 and 3 days of
Palladacycle Activity on Leishmania
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drug inhibited 84% and 96%, respectively, of parasite growth 1
day after treatment and nearly 100% of promastigotes were killed
after 2 and 3 days in the presence of these concentrations of DPPE
1.2. A growth curve similar to control was observed when L. (L.)
amazonensis promastigotes were cultured in the presence of the
highest concentration of DMSO used for DPPE 1.2 solubilization
(0.04%). As a control drug parasites were grown in the presence of
amphotericin B. After 72 of incubation, the IC50 values for both
drugs were determined (Table 1).
Leishmanicidal activity of DPPE 1.2 on L. (L.) amazonensis-
infected macrophages
Treatment with DPPE 1.2 resulted in a significant, dose-
dependent decrease in infection index of L. (L.) amazonensis-
infected macrophages with an inhibition of 92% for 500 nM of
DPPE 1.2 (IC50 of 128.35 nM; 95% confidence limits, 111.2–
164.2 nM) (Figure 2A). Infected cultures were also treated with the
highest concentration of DMSO used for DPPE 1.2 solubilization
(0.04%); these concentrations did not reduce the viability or the
infection of macrophages (data not shown). The cytotoxicity of
DPPE 1.2 on macrophages was evaluated by the MTT method
and the CC50 was determined (1,267 nM; 95% confidence limits,
1,15–1,52 nM).
Leishmanicidal effect on intracellular amastigotes was also
observed in the presence of Glucantime. However, in comparison
to DPPE 1.2, significant higher concentrations of this antimonial
were used for parasite destruction (Figure 2B). The IC50 value
expressed as mg/ml of pentavalent antimony [Sb
v] was 178.5 mg/ml
(95% confidence limits, 108.1–294.6 mg/ml) and treatment with the
drug at this concentration resulted in 40% of macrophage toxicity
(data not shown). The calculated CC50 for Glucantime expressed as
mg/ml of pentavalent antimony [Sb
v] was 266.3 mg/ml (95%
confidence limits, 252.2–290.3 mg/ml).
Effect of DPPE 1.2 on BALB/c mice infected with L. (L.)
amazonensis
BALB/c mice infected with L. (L.) amazonensis were treated
every other day with 320 mg/kg/day of DPPE 1.2 for 1 month
injected in foot lesions. As can be observed in Figure 3, starting
from 24 days of treatment the animals which received DPPE 1.2
showed a significant decrease of foot lesion size compared to
controls. Starting from 16 days of treatment, the animals that
received Glucantime also exhibited significantly smaller foot
lesions compared to untreated control, as well as to animals
treated with DPPE 1.2.
Parasite load was also evaluated by limiting dilution in foot
lesions of BALB/c mice one month after end of the treatment with
either DPPE 1.2 or Glucantime. Figure 4 shows that BALB/c
mice treated with either DPPE 1.2 or Glucantime displayed a
reduction of parasite load of 97% and 99%, respectively,
compared to untreated animals.
To evaluate hepato and nephrotoxicity of DPPE 1.2 serum
levels of transaminases, urea and creatinine were determined. No
statistically significant alterations were detected between groups
(data not shown).
Effect of DPPE 1.2 on proteolytic activity of L. (L.)
amazonensis
Parasite proteolytic activity was determined by zymography
after electrophoresis of L. (L.) amazonensis extracts in SDS-PAGE
with gelatin coupled gels. Figure 5A shows that most of the
proteolytic activity of L. (L.) amazonensis promastigotes that
migrates as a 60 kDa band was abolished in the presence of
orthophenanthroline, while DPPE 1.2 did not show any effect on
this activity. On the other hand, amastigotes displayed a strong
activity at a molecular mass of 30–35 kDa that was totally
inhibited by either DPPE 1.2 or E-64, indicating that DPPE 1.2
inhibits cysteine protease activity of L. (L.) amazonensis amastigotes.
A spectrofluorometric assay using specific substrates for
cathepsins in the presence of DPPE 1.2 was also carried out.
Table 1. In vitro activity of DPPE 1.2 and amphotericin B on L.
(L.) amazonensis promastigotes.
Drug IC50 (nM)
a CI 95%
b
DPPE 1.2 2.13 2.02–2.24
Amphotericin B 15.58 9.1–22.6
aValues were calculated after 72 h of incubation with the drugs and are
representative of three independent experiments.
b95% confidence interval.
doi:10.1371/journal.pntd.0001626.t001
Figure 2. Effect of DPPE 1.2 and Glucantime on intracellular L. (L.) amazonensis amastigotes. Macrophages were infected with amastigotes
of L. (L.) amazonensis for 24 h at 37uC, the drugs were added and infection index was calculated after 72 h of treatment.
*P,0.001 and
#P,0.05
compared to control.
doi:10.1371/journal.pntd.0001626.g002
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exhibited high hydrolytic activity on all substrates tested. Although
DPPE 1.2 inhibited the enzymatic activity on all substrates, a
significantly higher reduction on cathepsin B activity could be
observed in the presence of this palladacycle complex (75%).
Figure 5C shows that the activity of L. (L.) amazonensis extract on a
most specific substrate for cathepsin B was significantly inhibited
either by DPPE 1.2 or CA074 (data not shown). The calculated
IC50 values for DPPE 1.2 and CA074 were not significantly
different (2.2560.11 mM and 0.760.08 mM, respectively), strongly
suggesting that DPPE 1.2 inhibits L. (L.) amazonensis cathepsin B.
Discussion
The present results document the leishmanicidal effect of the
palladacycle complex DPPE 1.2 on L. (L.) amazonensis. This
compound destroyed L. (L.) amazonensis promastigotes at very low
concentrations. Extension of this study to L. (L.) amazonensis-
infected macrophages also showed an effective leishmanicidal
activity of DPPE 1.2 against amastigotes, whereas the drug
displayed 10-fold less toxicity to macrophages. Although similar
leishmanicidal effect was observed with Glucantime, significantly
higher concentrations of this antimonial were necessary to destroy
L. (L.) amazonensis amastigotes. The leishmanicidal activity of
DPPE 1.2 is comparable to that obtained with several compounds
tested against L. (L.) amazonensis like mesoionic salt derivatives,
primary S-nitrosothiols, aureobasidin A, julocrotine, tamoxifen,
elatol [28–33]. However, higher concentrations of these com-
pounds were used to destroy L. (L.) amazonensis, whereas an
effective leishmanicidal effect was observed with DPPE 1.2 at
nanomolar range. The leishmanicidal activity of metal complexes
of gold, platinum, iridium, rhodium and osmium has also been
investigated. However, most of them destroyed only L. (L.) donovani
promastigotes, while few reduced the parasitism in infected
animals [34–36], impairing the comparison with DPPE 1.2 data.
Among other palladium complexes previously tested against
Leishmania only one was an effective inhibitor of promastigote
growth, while none of them reduced the intracellular amastigote
burden [18].
The leishmanicidal effect of DPPE 1.2 was also demonstrated in
vivo. Although the reduction of parasite load in foot lesions of L.
(L.) amazonensis-infected mice treated with DPPE 1.2 was similar to
that obtained with Glucantime, this antimonial compound was
used in 200 times higher concentration. Treatment with DPPE 1.2
led to a significant reduction of parasite load in foot lesions (97%),
but did not result in sterile cure in infected mice. However, it is
important to emphasize that the BALB/c strain is highly
susceptible to L. (L.) amazonensis infection. These mice develop a
gradual increase of foot lesions characterized by a large infiltrate of
macrophages harboring a high number of amastigotes, thus
mimicking the anergic form of diffuse cutaneous leishmaniasis
caused by L. (L.) amazonensis [2]. The apparent lack of toxicity of
DPPE 1.2 to BALB/c mice was demonstrated by hepatic and
renal function assays after treatment with the drug, corroborating
data that showed the low toxicity of palladacycle complexes in the
treatment of mice against tumor cells [16]. More recently, the high
Figure 3. Effect of DPPE 1.2 on BALB/c mice infected with L. (L.) amazonensis. A -Development of foot lesions in L. (L.) amazonensis-infected
BALB/c mice treated with DPPE 1.2. The treatment was started 15 days after infection and continued for 5 weeks. Data points represent the average
measurements for 3 groups of twelve mice each; B - Macroscopical evaluation of lesions in untreated (left column), DPPE 1.2-treated mice (medium
column), and Glucantime-treated mice (right column) 60 days post-infection.
*P,0.01 and
**P,0.001 compared to untreated animals;
#P,0.001
compared to animals treated with DPPE 1.2. Data are representative of three independent experiments.
doi:10.1371/journal.pntd.0001626.g003
Figure 4. Parasite load in foot lesions of L. (L.) amazonenis-
infected BALB/c mice treated with DPPE 1.2. Number of parasites
recovered by limiting dilution from L. (L.) amazonensis-infected mice
treated with DPPE 1.2. Parasites were quantified one month after
interruption of treatment.
*P,0.001.
doi:10.1371/journal.pntd.0001626.g004
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cidal activity was also demonstrated, suggesting the use of this
compound for treatment of Chagas’ disease [19].
As reported in the literature, the antitumor property of
palladacycle complexes can be attributed, at least in part, to their
inhibitory activity on the cysteine protease cathepsin B [21]. This
information led us to test for the possible effect of DPPE 1.2 on L.
(L.) amazonensis protease activity. We showed that DPPE 1.2 did
not inhibit the activity of the metalloprotease gp63, the major
surface protein of Leishmania promastigotes [37]. On the other
hand, the high cysteine protease activity expressed in L. (L.)
amazonensis amastigotes was inhibited by DPPE 1.2 and the most
significant inhibition was observed on the cathepsin B activity.
However, the drug did not affect the cysteine proteinase activity of
mouse macrophages (data not shown). Several studies demon-
strated the involvement of cathepsin L-like (cpL) and cathepsin B-
like (cpB) in Leishmania growth and virulence in vitro and in vivo [38–
40]. Furthermore, cysteine proteinase inhibitors have been
reported to kill Leishmania in vitro and in vivo [8–10]. In the present
study we show that in vitro DPPE 1.2 inhibited L. (L.) amazonensis
cathepsin B at higher concentrations than those necessary to kill L.
(L.) amazonensis. These findings argue against a relationship
between the leishmanicidal effect of DPPE 1.2 and the inhibition
of L. (L.) amazonensis cathepsin B and suggest that other relevant
targets may account for the leishmanicidal effect of the drug.
Palladacycle complexes have been associated with organelle-
specific effects in tumor cells such as the lysosomal and
mitochondrial permeabilization that can trigger apoptosis
[41,42]. The induction of L. (L.) amazonensis apoptosis by DPPE
1.2 has not been investigated.
Leishmania killing is associated to macrophage activation by IFN-
c and TNF-a and the production of nitric oxide [43], whereas
TGF-b is an immunosupressor cytokine known to exacerbate
visceral and cutaneous leishmaniasis [44–47]. Interestingly,
Leishmania cathepsin B is involved in the conversion of latent
TGF-b to its biologically active form [48]. Since we have shown
here that DPPE 1.2 inhibits parasite cathepsin B, killing of L. (L.)
amazonensis in infected mice treated with the drug may be
associated to protective responses arising from lower expression
of the active form of TGF-b. This possibility is now under
investigation.
In conclusion, the effectiveness of DPPE 1.2 in destroying L. (L.)
amazonensis in vitro and by intralesional administration in vivo at
concentrations non toxic to the host support further studies of the
leishmanicidal activity of the palladacycle as an additional choice
to available chemotherapies.
Figure 5. Effect of DPPE 1.2 on proteolytic activity of L. (L.) amazonensis. A - Extracts of promastigotes (P) and amastigotes (AM) of L. (L.)
amazonensis were separated by SDS-PAGE on a 10% acrylamide gel containing 0.1% gelatin under nonreducing conditions. Numbers at left indicate
apparent molecular masses in kilodaltons. B - Fluorogenic substrates with different specificities for cathepsin-like proteases were incubated with
extracts of L. (L.) amazonensis amastigotes in absence or presence of DPPE 1.2, as indicated. C – Fluorogenic substrate specific for cathepsin B-like
proteases was incubated with extracts of L. (L.) amazonensis in presence of increasing concentrations of DPPE 1.2.
doi:10.1371/journal.pntd.0001626.g005
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